Celon Pharma Reports Positive Phase 2 Results for PDE10A Inhibitor in Parkinson’s Disease Dyskinesia ##

CPL'36 is an oral, once-daily PDE10A inhibitor developed by Celon Pharma
Phase 2 trial in 105 patients with levodopa-induced dyskinesia in Parkinson's disease

Met primary endpoint of improving Unified Dyskinesia Rating Scale (UDysRS) total score at 4 weeks:

20 mg dose:
12.30 point improvement vs placebo (p<0.001)

40 mg dose:
13.58 point improvement vs placebo (p<0.001)
Showed statistically significant improvement in UDysRS objective subscale from day 7
Generally well-tolerated, with somnolence as most common side effect
First clinical trial demonstrating efficacy of PDE10A inhibition for dyskinesia in Parkinson's disease
Builds on positive Phase 2 results previously reported in schizophrenia in 2024
Celon Pharma believes CPL'36 has potential to significantly advance Parkinson's disease treatment
Next steps likely include larger Phase 3 trials to confirm efficacy and safety

This novel PDE10A inhibitor shows promise as a potential new treatment option for levodopa-induced dyskinesia, a common and debilitating side effect of long-term Parkinson's disease therapy157.

Sources:

1. https://www.mabion.eu/science-hub/science-news/dyskinesias-in-parkinsons-disease-promising-new-treatment-approach/

5. https://www.marketscreener.com/quote/stock/CELON-PHARMA-S-A-32078312/news/Celon-Pharma-S-A-Announces-Strong-Proof-of-Concept-Data-from-Phase-2-Trial-of-PDE10A-Inhibitor-CPL-49241678/

7. https://www.clinicaltrialvanguard.com/news/celon-pharma-promising-phase-2-data-for-pde10a-inhibitor-in-parkinsons-dyskinesia/